Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has received an average recommendation of "Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $18.60.
Several analysts have recently commented on the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Monday, May 19th. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price for the company.
Check Out Our Latest Research Report on Atyr PHARMA
Atyr PHARMA Stock Performance
Shares of NASDAQ:ATYR traded up $0.17 on Thursday, reaching $4.43. The company's stock had a trading volume of 1,716,548 shares, compared to its average volume of 948,831. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66. The stock has a market capitalization of $394.29 million, a P/E ratio of -4.71 and a beta of 0.79. The stock's 50-day moving average is $3.26 and its two-hundred day moving average is $3.44. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. As a group, sell-side analysts forecast that Atyr PHARMA will post -0.91 EPS for the current year.
Institutional Trading of Atyr PHARMA
Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new stake in shares of Atyr PHARMA during the 4th quarter worth about $53,093,000. Point72 Asset Management L.P. purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at approximately $17,677,000. Octagon Capital Advisors LP boosted its position in Atyr PHARMA by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after acquiring an additional 2,652,000 shares during the last quarter. Tikvah Management LLC acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $8,908,000. Finally, Woodline Partners LP purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $6,092,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
Atyr PHARMA Company Profile
(
Get Free ReportaTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
